New Antivirals and Drug Resistance
- 1 June 2009
- journal article
- review article
- Published by Annual Reviews in Annual Review of Biochemistry
- Vol. 78 (1) , 95-118
Abstract
Progress in the discovery of new antiviral medicines is tempered by the rapidity with which drug-resistant variants emerge. A review of the resistance-suppressing properties of four classes of antivirals is presented: influenza virus neuraminidase inhibitors, HIV protease inhibitors, antibodies, and protein-based fusion inhibitors. The analysis supports the hypothesis that the more similar the drug is to the target's natural ligands, the higher the barrier to resistance. However, other factors, such as entropy compensation and solvent anchoring, might also be exploited for improved drug design.Keywords
This publication has 124 references indexed in Scilit:
- Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and DarunavirJournal of Molecular Biology, 2008
- The contents of the syringeNature, 2008
- Potent D-peptide inhibitors of HIV-1 entryProceedings of the National Academy of Sciences, 2007
- Structural basis of viral invasion: lessons from paramyxovirus FCurrent Opinion in Structural Biology, 2007
- Conformational flexibility in the flap domains of ligand-free HIV proteaseActa Crystallographica Section D Structural Biology, 2007
- Structure of a High-affinity “Mimotope” Peptide Bound to HIV-1-neutralizing Antibody b12 Explains its Inability to Elicit gp120 Cross-reactive AntibodiesJournal of Molecular Biology, 2007
- HIV-1 protease and reverse transcriptase mutations for drug resistance surveillanceAIDS, 2007
- Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibodyNature Structural & Molecular Biology, 2006
- The Protein Data BankNucleic Acids Research, 2000
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994